Hold Aurobindo Pharma; target of Rs 665: KR Choksey
In Q4FY23, Aurobindo reported a revenue of INR 64,730 Mn (+11.04% YoY and +1.0% QoQ) The net profit for the quarter stood at INR 5,109 Mn (-11.4% Yoy and +4.1% QaQ) During the quarter, EBITDA grew by 2.9%YoY and 5% QeQ to INR 10,022 Mn.
In Q4FY23, Aurobindo reported a revenue of INR 64,730 Mn (+11.04% YoY and +1.0% QoQ) driven by healthy growth in US/ ROW markets and the API business. For FY23, the company reported a revenue of INR 2,48,553.8 Mn. During the quarter, EBITDA grew by 2.9% YoY and 5% QoQ to INR 10,022 Mn. The margins contracted by 129 bps YoY to report to 15.5%(+59 bps QoQ), the dip in the margins was as a result of change in product mix and one off expenses of INR 400-450 mn. The net profit for the quarter stood at INR 5,109 Mn (-11.4% YoY and +4.1% QoQ). The net profit margins contracted by 203bps YoY( +23bps QoQ) .EPS during the quarter stood at INR 8.6 against INR 8.2 in Q3FY23 and INR 9.8 in Q4FY22.
Mojo Stocks - The Top 1% Picks across Markets
{{col.header}}
Latest
OPEN CALL
CLOSED CALL
{{s[col.key]}}
{{s.change_value}}
{{ s.score.value }} - {{ s.score.call_type }}
{{ s.dot_summary.score }} - {{ s.dot_summary.scoreText }}
{{s[col.key]}}
{{col.extra}}
Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
![]( "Upgrade & View All Insights")
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read